Empagliflozin ameliorates the cardiac energy-deficient state, improves cardiac function and reduces myocardial cellular volume in patients with type 2 diabetes

6 May 2021 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Recent trials and breaking studies Epidemiology, Prognosis, Outcome EACVI Premium Access EuroCMR 2021

ESC 365 is supported by

ESC 365 is supported by